Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries.

Parkinson’s disease Parkinson’s disease nurse specialists Thailand apomorphine infusion developing countries device-aided therapy motor complications specialist centers treatment accessibility

Journal

Expert review of neurotherapeutics
ISSN: 1744-8360
Titre abrégé: Expert Rev Neurother
Pays: England
ID NLM: 101129944

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 19 5 2020
medline: 18 5 2021
entrez: 19 5 2020
Statut: ppublish

Résumé

The increasing global burden of Parkinson's disease (PD) poses a particular challenge for developing countries, such as Thailand, when delivering care to a geographically diverse populace with limited resources, often compounded by a lack of expertise in the use of certain PD medications, such as device-aided therapies (DAT). A panel of local, regional, and international PD experts convened to review the unmet needs of PD in Thailand and share insights into effective delivery of DAT, focusing on experience with apomorphine infusion. Despite its proven efficacy and safety, implementation of apomorphine infusion as a new option was not straightforward. This has prompted a range of health-care professional and patient-focused initiatives, led by the Chulalongkorn Center of Excellence for Parkinson's Disease and Related Disorders in Bangkok, to help establish a more coordinated approach to PD management throughout the country and ensure patients have access to suitable treatments. Overcoming the challenges of education, proficiency, resource capacity and standard of care for PD patients in developing countries requires a coordinated effort both nationally and beyond. The best practices identified in Thailand following the introduction of apomorphine infusion might be helpful for other countries when implementing similar programs.

Identifiants

pubmed: 32421371
doi: 10.1080/14737175.2020.1770598
doi:

Substances chimiques

Antiparkinson Agents 0
Apomorphine N21FAR7B4S

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

523-537

Auteurs

Roongroj Bhidayasiri (R)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Onanong Phokaewvarangkul (O)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Karn Sakdisornchai (K)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Kamolwan Boonpang (K)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

K Ray Chaudhuri (KR)

The Maurice Wohl Clinical Neuroscience Institute, King's College London and National Parkinson Foundation Centre of Excellence, King's College Hospital , London, UK.

Jan Parsons (J)

The Walton Centre for Neurology and Neurosurgery , Liverpool, UK.

Praween Lolekha (P)

Division of Neurology, Department of Medicine, Thammasat University Hospital , Pathumthani, Thailand.

Parnsiri Chairangsaris (P)

Division of Neurology, Department of Medicine, Phra Mongkutklao Hospital , Bangkok, Thailand.

Prachaya Srivanitchapoom (P)

Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University , Bangkok, Thailand.

Sharon Benedierks (S)

Stada Pharmaceuticals , Sydney, Australia.

Pattamon Panyakaew (P)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Thanatat Boonmongkol (T)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Yuwadee Thongchuam (Y)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Nitinan Kantachadvanich (N)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Saisamorn Phumphid (S)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Andrew H Evans (AH)

Department of Neurology, Royal Melbourne Hospital , Melbourne, Australia.

Akravudh Viriyavejakul (A)

Prasat Neurological Institute , Bangkok, Thailand.

Apichart Pisarnpong (A)

Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University , Bangkok, Thailand.

Teus van Laar (T)

Department of Neurology, University of Groningen , Groningen, The Netherlands.

Priya Jagota (P)

Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society , Bangkok, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH